1、novotech-AUGUST 28,2023Primary Biliary Cholangitis Global Clinical trial landscape(2023)Global incidence and prevalence rates of PBC in 2020 were 1.76 and 14.60 per 100,000 people,respectivelyPBC rates difer globally,with higher rates in Asia Pacific and EuropeIn Asia Pacific,prevalence was higher i

2、n females,with South Korea leadingIn Europe Greece takes the lead where-as in the US,Canada takes the leadAPAC contributed 40%of PBC trials,notably driven by Mainland ChinaUS and Europe conducted 40%of PBC trials;the US led in North America,UK in EuropeAPAC demonstrated accelerated recruitment rates

3、,establishing itself as an efcient clinical trial hubThe US saw the highest CAGR increase,while APAC and Europe experienced moderate growth in the last decadePBCPrimary biliary cholangitis(PBC)is a chronic liver illness that damages the T-cell bile ductsPredomi-nantly afects females aged 30-40,with

4、a female-to-male ratio of about 4-6:1PRIMARY BILIARY CHOLANGITISGLOBAL CLINICAL TRIAL LANDSCAPE The content of this publication is proprietary to Novotech Health Holdings.No part of this publication may be reproduced,distributed,or transmitted in any form or by any means,including photocopying,recor

5、ding,or other electronic or mechanical methods,without the prior written permission of Novotech except in the case of quotations embodied in reviews and non-commercial uses.Please note that this copyright statement applies specifically to this publication and its content and does not extend to other

6、 materials or intellectual property owned by Novotech.Any unauthorized reproduction or distribution of this publication or any portion thereof may result in legal action taken by Novotech to protect its rights.For permissions or inquiries,please contact:communicationsnovotech-Obeticholic acid,known